Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: Neurochemical and molecular substrates

Current Pharmaceutical Design

Volumn 11, Issue 8, 2005, Pages 947-962

  Hayley, Shawn ^a,b   Anisman, Hymie ^a  

^a CARLETON UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

Cytokine; Depression; Microglia; Neurochemical; Neurodegeneration; Neurotoxin; Parkinson's disease; Sensitization

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACUTE PHASE PROTEIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ALPHA INTERFERON; ANTIINFLAMMATORY AGENT; ARGIPRESSIN; BRAIN DERIVED NEUROTROPHIC FACTOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; GAMMA INTERFERON; HAPTOGLOBIN; IMMUNOGLOBULIN M; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; LEVODOPA; MONOAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARAQUAT; ROTENONE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALZHEIMER DISEASE; BACTERIAL INFECTION; BRAIN FUNCTION; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DEGENERATIVE DISEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; HEPATITIS C; HEPATITIS C VIRUS; HORMONE RELEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATORY CELL; INHIBITION KINETICS; JAPANESE ENCEPHALITIS VIRUS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MELANOMA; MENTAL DISEASE; MICROGLIA; MOLECULAR MECHANICS; MOOD; MOUSE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NERVE CELL; NERVE CELL LESION; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REVIEW; SENSITIZATION; STRESS; VIRUS INFECTION;

ANIMALS; BRAIN CHEMISTRY; CYTOKINES; DEPRESSIVE DISORDER; ENVIRONMENT; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 14744284712     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053381611     Document Type: Review

References (160)

1. Hayley S, Brebner K, Lacosta S, Merali Z, Anisman H. Sensitization effects of Tumor Necrosis Factor-a: neuroendocrine, central monoamine and behavioral variations. J Neurosci 1999; 19 (13): 5654-5665.
2. Hayley S, Lacosta S, Merali Z, van Rooijen N, Anisman H. Central Monoamine and Plasma Corticosterone Changes Induced by a Bacterial Endotoxin: Sensitization and Cross-sensitization Effects. Eur J Neurosci 2001; 13: 1155-1165.
3. Hayley S, Merali Z, Anisman H. The acute and sensitization effects of tumor necrosis factor-α: implications for immunotherapy as well as psychiatric and neurological conditions. Acta Neuropsychiat 2002; 14: 322-335.
4. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996; 211: 1 13-6.
5. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994; 165(1-2): 208-10.
6. Rothwell NJ. Cytokines - killers in the brain? J Physiol 1999; 514: 3-17.
7. Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995; 54(2): 276-81.
8. Carvey PM, Chang Q, Lipton JW, Ling Z. Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. Front Biosci 2003; 8: 826-37.
9. Ringheim GE, Conant K. Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). J Neuroimmunol 2004; 147: 43-9.
10. Anisman H, Hayley S, Turrin N, Merali Z. Stress, cytokines and depression. Inter J Neuropsychiat 2002; 5: 357-373.
11. Nemeroff CB. The role of corticotrophin-releasing factor in the pathogenesis of major depression. Pharmacopsychiatry 1988; 21: 76-82.
12. Bluthe RM, Dantzer R, Kelley KW. Central mediation of the effects of interleukin-1 on social exploration and body weight in mice. Psychoneuroendocrinology 1997; 22(l): 1-11.
13. Dunn A.J. Interactions between the nervous system and the immune system In: Psychopharmacology: The Fourth Generation of Progress (Bloom, F.E, Kupfer, D.J, eds). Raven Press, New York. 1995; pp 719-731.
14. Ericsson A, Kovacs KJ, Sawchenko PE. A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J Neurosci 1994; 14(2): 897-913.
15. Shintani F, Nakaki T, Kanba S, Sato K, Yagi G, Shiozawa M, et al. Involvement of interleukin-1 in immibilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. J Neurosci 1995; 15: 1961-1970.
16. Maier SF, Watkins LR. Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998; 105: 83-107.
17. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR, et al. Exposure to acute stress induces brain interleukin-1 beta protein in the rat. J Neurosci 1998; 18(6): 2239-46.
18. Pugh CR, Nguyen KT, Gonyea JL, Fleshner M, Watkins LR, Maier SF, et al. Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav Brain Res 1999; 106: 109-118.
19. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 1999; 461: 199-233.
20. Hayley S, Merali Z, Anisman H. Stress and cytokine-elicited neuroendocrine and neurotransmitter sensitization: implications for depressive illness. Stress 2003; 6(l): 19-32.
21. Merali Z, Lacosta S, Anisman H. Effects of interleukin-1 beta and mild stress on alterations of neuropinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study. Brain Res 1997; 761(2): 225-35.
22. Smith RS. The macrophage theory of depression. Med Hypotheses 1991; 35(4): 298-306.
23. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988; 12(2): 123-37.
24. Anisman H, Kokkinidis L, Borowski T, Merali Z. Differential effects of interleukin (IL)-lbeta, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res 1998; 779(1-2): 177-87.
25. Watanobe H, Takebe K. Intrahypothalamic perfusion with interleukin-1-beta stimulates the local release of corticotropin-releasing hormone and arginine vasopressin and the plasma adrenocorticotropin in freely moving rats: a comparative perfusion of the paraventricular nucleus and the median eminence. Neuroendocrinology 1993; 57(4): 593-9.
26. Tilders FJH, Schmidt ED, De Goeij DCE. Phenotypic plasticity of CRF neurons during stress. Ann NY Acad Sci 1993; 697: 39-52.
27. Webster EL, Torpy DJ, Elenkov IJ, Chrousos GP. Corticotropin-releasing hormone and inflammation. Ann NY Acad Sci 1998; 840: 21-32.
28. Bernardini R, Kamilaris TC, Calogero AE, Johnson EO, Gomez MT, Gold PW, et al. Interactions between tumor necrosis factor-α, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. Endocrinology 1990; 126, 2876-2881.
29. Van der Meer MJ, Hermus AR, Pesman GJ, Sweep CG. Effects of cytokines on pituitary beta-endorphin and adrenal corticosterone release in vitro. Cytokine 1996; 8(3): 238-47.
30. Turnbull AV, Rivier C. Corticotropin-releasing factor, vasopressin, and prostaglandins mediate, and nitric oxide restrains, the hypothalamic-pituitary-adrenal response to acute local inflammation in the rat. Endocrinology 1996; 137: 455-463.
31. Hayley S, Kelly O, Anisman H. Murine tumor necrosis factor-α sensitizes plasma corticosterone activity and the manifestation of shock: modulation by histamine. J. Neuroimmunol 2002; 131: 60-69.
32. Brebner K, Hayley S, Merali Z, Anisman H. Synergistic effects of interleukin-1β, interleukin-6 and tumor necrosis factor-a: Central monoamine, corticosterone and behavioral variations. Neuropsychopharmacol 1999; 22, 566-580.
33. Linthorst AC, Flachskamm C, Muller-Preuss P, Holsboer F, Reul JM. Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study. J Neurosci 1995 ; 15(4): 2920-34.
34. Shintani F, Kanba S, Nakaki T, Nibuya M, Kinoshita N, Suzuki E, et al. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci 1993; 13(8): 3574-81.
35. Ando T, Dunn AJ. Mouse tumor necrosis factor-alpha increases brain tryptophan concentrations and norepinephrine metabolism while activating the HPA axis in mice. Neuroimmunomodulation 1999; 6(5): 319-29.
36. Pauli S, Linthorst AC, Reul JM. Tumour necrosis factor-alpha and interleukin-2 differentially affect hippocampal serotonergic neurotransmission, behavioural activity, body temperature and hypothalamic-pituitary-adrenocortical axis activity in the rat. Eur J Neurosci 1998; 10(3): 868-878.
37. Kronfol Z. Immune dysregulation in major depression: a critical review of existing evidence. Int J Neuropsychopharmacol 2002; 5(4): 333-43.
38. Maes M, Scharpe S, Bosmans E, Vandewoude M, Suy E, Uyttenbroeck W, et al. Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16(4): 501-15.
39. Anisman, H. Stress, Immunity, Cytokines, and Depression. Acta Neuropsychiatrica 2002; 14: 251-262.
40. Anisman H, Ravindran AV, Griffiths J, Merah Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999; 4(2): 182-188.
41. Nunes SO, Reiche EM, Morimoto HK, Matsuo T, Itano EN, Xavier EC, et al. Immune and hormonal activity in adults suffering from depression. Braz J Med Biol Res 2002; 35(5): 581-587.
42. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, et al. Illness, cytokines, and depression. Ann NY Acad Sci 2000; 917: 478-487.
43. Capuron L, Ravaud A, Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med 2001; 63(3): 376-86.
44. Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 1998; 33(3): 251-4.
45. Ramamoorthy S, Blakely RD. Phosphorylation and sequestration of scrotonin transporters differentially modulated by psychostimulants. Science 1999; 285(5428): 763-6.
46. Wichers MC, Maes M. The role of indoleamine 2, 3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004; 29(l): 11-7.
47. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160(8): 1516-8
48. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatr 2000; 157(l): 115-8.
49. Kempermann G, Kronenberg G. Depressed new neurons--adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry 2003; 54(5): 499-503.
50. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38(2): 157-60.
51. Jacobs BL. Adult brain neurogenesis and depression. Brain Behav Immun 2002; 16(5): 602-9.
52. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray NA, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychia 2003; 53(8): 707-42.
53. Hellsten J, Wennstrom M, Mohapel P, Ekdahl CT, Bengzon J, Tingstrom A. Electroconvulsive seizures increase hippocampal neurogenesis after chronic corticosterone treatment. Eur J Neurosci 2002; 16(2): 283-90.
54. Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacol 2003; 28(9): 1562-71.
55. Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrie P. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 2003; Dec 23 [Epub ahead of print].
56. McEwen BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci 2001; 933: 265-77.
57. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000; 48(8): 755-65.
58. Lucassen PJ, Muller MB, Holsboer F, Bauer J, Holtrop A, Wouda J, el al. Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol 2003; 158(2): 453-68.
59. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 2004; 161(l): 109-15.
60. Manji HK, Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychia 2002; 7 Suppl 1: S46-56.
61. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54(l): 70-5.
62. Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999; 46(9): 1181-91.
63. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22(8): 3251-61.
64. Curtis J, Finkbeiner S. Sending signals from the synapse to the nucleus: possible roles for CaMK, Ras/ERK, and SAPK pathways in the regulation of synaptic plasticity and neuronal growth. Neurosci Res 1999; 58(l): 88-95.
65. Eom DS, Choi WS, Oh YJ. Bcl-2 enhances neurite extension via activation of c-Jun N-terminal kinase. Biochem Biophys Res Commun 2004; 314(2): 377-81.
66. Ying SW, Futter M, Rosenblum K, Webber MJ, Hunt SP, Bliss TV, et al. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Are synthesis. J Neurosci 2002; 22(5): 1532-40.
67. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2003; 35(2): 5-49.
68. Capuron L, Neurauter G, Musselman DL, Lawson DH Nemeroff CB, Fuchs D, et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54(9): 906-14.
69. Hanisch UK. Microglia as a source and target of cytokines. Glia 2002; 40(2): 140-55.
70. Pocock JM, Liddle AC. Microglial signalling cascades in neurodegenerative disease. Prog Brain Res 2001; 132: 555-65,
71. Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry 1999; 14(9): 711-8.
72. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003; 18(4): 414-8.
73. Barone FC, White RF, Spera PA, Ellison J, Currie RW, Wang X, et al. Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression. Stroke 1998; 29(9): 1937-50.
74. Sheng JG, Griffin WS, Royston MC, Mrak RE. Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer's disease. Neuropathol Appl Neurobiol 1998; 24(4): 278-83.
75. Woodroofe MN. Cytokine production in the central nervous system. Neurology 1999; 45(6 Suppl 6): S6-10.
76. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996; 26(7): 788-94.
77. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1998; 334(6180): 345-48.
78. Bonnet AM, Houeto JL. Pathophysiology of Parkinson's disease. Biomed Pharmacother 1999; 53(3): 117-21.
79. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 25; 219(4587): 979-80.
80. Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 2000; 62(l): 63-88.
81. Salach JI, Singer TP, Castagnoli N Jr, Trevor A. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem Biophys Res Commun 1984; 125(2): 831-5.
82. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci 1996; 14; 93(10): 4565-71.
83. Sedelis M, Schwarting RK, Huston JP. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001; 125(1-2): 109-125.
84. Hirsch EC, Hoglinger G, Rousselet E, Breidert T, Parain K, Feger J, et al. Animal models of Parkinson's disease in rodents induced by toxins: an update. J Neural Transm Suppl 2003; 65: 89-100.
85. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001; 65(2): 135-72.
86. Lansbury PT, Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Genet Dev 2002; 12(3): 299-306.
87. Jenner P. Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci 2001; 24(5): 245-7.
88. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002; 10(2): 119-127.
89. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci 2000; 20, 9207-14.
90. Di Monte DA. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2003; 2(9): 531-8.
91. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3(12): 1301-6.
92. Chan-Palay V. Depression and dementia in Parkinson's disease. Catecholamine changes in the locus ceruleus, a basis for therapy. Adv Neurol 1993; 60: 438-46.
93. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003; 23(34): 10756-64.
94. Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 1998; 44(3 Suppl 1): S110-4.
95. Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A, Peter D, Stefano G. Immune processes in the pathogenesis of Parkinson's disease: a potential role for microglia and nitric oxide. Med Sci Monit 2002; 8(8): RA165-77.
96. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999; 156(l): 50-61.
97. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002; 81, 1285-1297.
98. McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration. Ann Neurol 2003; 54(5): 599-604.
99. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH. Age-related microglial activation in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003; 964(2): 288-94.
100. Wu DC, Teismann P, Tien K, Vila M, Jackson-Lewis V, Ischiropoulos H, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003; 100(10): 6145-50.
101. Gao HM, Liu B, Zhang W, Hong JS. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB 2003; 17(13): 1954-6.
102. Rossi D, Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003; 88(2): 212-8.
103. Patel HC, Boutin H, Allan SM. Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann N Y Acad Sci 2003; 992: 39-47.
104. Lawrence CB, Allan SM, Rothwell NJ. Interleukin-1 beta and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur J Neurosci 1998; 10(3): 1188-95.
105. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001; 4(7): 702-10.
106. Takahashi M, Yamada T. Viral etiology for Parkinson's disease--a possible role of influenza A virus infection. Jpn J Infect Dis 1999; 52: 89-98.
107. Tsui JK, Calne DB, Wang Y, Schulzer M, Marion SA. Occupational risk factors in Parkinson's disease. Can J Public Health 1991; 90: 334-7.
108. Casals J, Elizan TS, Yahr MD. Postencephalitic parkinsonism--a review. J Neural Transm 1998; 105, 645-76
109. Dickman MS. von Economo encephalitis. Arch Neurol 2001; 58(10): 1696-8.
110. Mattock C, Marmot M, Stern G. Could Parkinson's disease follow intra-uterine influenza?: a speculative hypothesis. J Neurol Neurosurg Psychiatry 1988; 51(6): 753-6.
111. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P. Parkinsonism in HIV dementia, J Neural Transm 2002; 109(5-6): 767-75.
112. Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol 2000; 47(2): 186-94.
113. Ogata A, Tashiro K, Nukuzuma S, Nagashima K, Hall WW. A rat model of Parkinson's disease induced by Japanese encephalitis virus. J Neurovirol 1997; 3(2): 141-7.
114. McGeer PL, Yasojima, K, McGeer EG. Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease. Neurosci Lett 2002; 326(l): 67-9.
115. Abramsky O, Litvin Y. Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia. Perspect Biol Med 1978; 22(l): 104-14.
116. Dale RC, Church AJ, Surtees RA, Lees AJ, Adcock JE, Harding B, et al. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 2004; 127: 21-33.
117. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 2001; 21(21): 8447-55.
118. Rowe DB, Le W, Smith RG, Appel SH. Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J Neurosci Res 1998; 53: 551-558.
119. He Y, Le WD, Appel SH. Role of Fcγ Receptors in Nigral Cell Injury Induced by Parkinson Disease Immunoglobulin Injection into Mouse Substantia Nigra. Exp Neurol 2002; 176: 322-327,
120. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 2000; 20, 6309-6316.
121. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003; 17(l): 13-9.
122. Jeohn GH, Kong LY, Wilson B, Hudson P, Hong JS. Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures. J Neuroimmunol 1998; 85(l): 1-10.
123. Chao CC, Hu S, Ehrlich L, Peterson PK. Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun 1995; 9: 355-365.
124. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000; 60: 277-290.
125. Mandel S, Grunblatt E, Youdim M. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J Neural Transm Suppl 2000; (60): 117-124.
126. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 2003; 18(10): 2731-2742.
127. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 2002; 16(11): 1474-1476.
128. Rousselet E, Callebert J, Parain K, Joubert C, Hunot S, Hartmann A, et al. Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp Neurol 2002; 177(l): 183-192.
129. Hayley S, Crocker SJ, Smith P, Shree T, Park DS. Mice lacking the tumor necrosis factor-α or Fas receptors are resistant to MPTP induced death of dopaminergic neurons. J Neurosci 2004; 24: 2045-2053.
130. Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, Di Monte D. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem 2002; b83(1): 167-75.
131. Lee SJ, Zhou T, Choi C, Wang Z, Benveniste EN. Differential regulation and function of Fas expression on glial cells. Immunol 2000; 164(3): 1277-85.
132. Hartmann A, Mouatt-Prigent A, Faucheux BA, Agid Y, Hirsch EC. FADD: A link between TNF family receptors and caspases in Parkinson's disease. Neurology 2002; 58: 308-310.
133. Hartmann A, Michel PP, Troadec JD, Mouatt-Prigent A, Faucheux BA, Ruberg M, et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J Neurochem 2001; 76(6): 1785-93.
134. Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PA, et al. Fas (CD95) Induces Proinflammatory Cytokine Responses by Human Monocytes and Monocyte-Derived Macrophages. J Immunol 2003; 70: 6209-6216.
135. Miller DB, Reinhard JF Jr, Daniels AJ, O'Callaghan JP. Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium. J Neurochem 1991; 57: 541-549.
136. Takahashi RN, Rogerio R, Zanin M. Maneb enhances MPTP neurotoxicity in mice. Res Common Chem Pathol Pharmacol 1989; 66: 167-170.
137. Bartanusz V, Jezova D, Bertini LT, Tilders FJ, Aubry JM, Kiss JZ. Stress-induced increase in vasopressin and corticotropin-releasing factor expression in hypophysiotrophic paraventricular neurons. Endocrinology 1993; 132: 895-902.
138. de Goeij DC, Jezova D, Tilders FJH. Repeated stress enhances vasopressin synthesis in corticotropin releasing factor neurons in the paraventricular nucleus. Brain Res 1992; 577: 165-168.
139. de Goeij DC, Kvetnansky R, Whitnall M, Jezova D, Berkenbosch F, Tilders FJH. Repeated stress-induced activation of corticotrophin-releasing factor neurons enhances vasopressin stores and colocalization with corticotrophin-releasing factor in the median eminence of rats. Neuroendocrinology 1991; 53: 150-159.
140. Schmidt ED, Binnekade R, Janszen AW, Tilders FJ. Short stressor induced long-lasting increases of vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult rats. J Neuroendocrinol 1997; 8: 703-712.
141. Tilders FJH, Schmidt ED. Cross-sensitization between immune and non-immune stressors. A role in the etiology of depression? Adv Exp Med Biol 1999; 461: 179-197.
142. Schmidt ED, Janszen AWJW, Wouterlood FG, Tilders FJH. Interleukin-1 induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH) neurons and hyperresponsiveness of the hypothalamic-pituitary-adrenal axis. J Neurosci 1995; 15: 7417-7426.
143. Anisman H, Turrin N, Merali Z, Hayley S. Neurochemical Sensitization Associated with Systemic administration of Tumor Necrosis Factor-α: Adjuvant Action in Combination with Bovine Serum Albumin. J Neuroimmunol 2004; 145(1-2): 91-102.
144. Hayley S, Staines W, Merali Z, Anisman H. Time-dependent sensitization of corticotropin releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-α. Neuroscience 2001; 106: 137-148.
145. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58(5): 445-452.
146. Connor T, Song C, Leonard BE, Merali Z, Anisman H. An assessment of the effects of central interleukin-1β, -2, -6 and tumor necrosis factor-α administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience 1998; 84: 923-933.
147. Hayley S, Wall P, Anisman H. Sensitization to the Neuroendocrine, Central Monoamine and Behavioral Effects of murine Tumor Necrosis Factor-α: Peripheral and central mechanisms. Eur J Neurosci 2002; 15: 1061-1076.
148. Ignatowski TA, Noble BK, Wright JR, Gorfien JL, Heffner RR, Spengler RN. Neuronal-associated tumor necrosis factor (TNF alpha): its role in noradrenergic functioning and modification of its expression following antidepressant drug administration. J Neuroimmunol 1997; 79(l): 84-90.
149. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 60(7): 1342-1345.
150. Gisslinger H, Svoboda T, Clodi M, Gilly B, Ludwig H, Havelec L, et al. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 1993; 57(3): 489-495.
151. Plata-Salaman CR, Sonti G, Borkoski JP, Wilson CD, French-Mullen JM. Anorexia induced by chronic central administration of cytokines at estimated pathophysiological concentrations. Physiol Behav 1996; 60(3): 867-875.
152. Shanks N, Windle RJ, Perks PA, Harbuz MS, Jessop DS, Ingram CD, et al. Early-life exposure to endotoxin alters hypothalamic-pituitary-adrenal function and predisposition to inflammation. Proc Natl Acad Sci USA 2000; 97: 645-650.
153. Ling ZD, Chang Q, Lipton JW, Tong CW, Landers TM, Carvey PM. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 2004; 124(3): 619-28.
154. Liu B, Gao HM, Hong JS. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 2003; 111(8): 1065-1073.
155. Blasko I, Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging 2003; 20(2): 101-13.
156. Herman JP, Cullman WE. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 1997; 20(2): 78-84.
157. Bokor M, Farago A, Garam T, Malatinszky G, Schnabel R. Anti body-dependent cell-mediated cytotoxicity (ADCC) in Parkinson's disease. J Neurol Sci 1993; 115(l): 47-50.
158. Ananth J, Parameswaran S, Gunatilake S. Antipsychotic polypharmacy. Curr Pharm Design 2004; 10(l8): 2231-8.
159. Asanuma M, Miyazaki I, Ogawa N. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharm Design 2004; 10(6): 695-700.
160. Campiani G, Fattorusso C, De Angelis M, Catalanotti B, Butini S, Fattorusso R, et al. Neuronal high-affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases. Curr Pharm Design 2003; 9(8): 599-625.